Abstract The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a
meeting to establish evidence-based recommendations for using tests to diagnose …

P neumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with
cancer‐related immunosuppression. There are well‐defined patients who are at risk of PJP …

Pneumocystis jirovecii can cause life-threatening pneumonia following treatment for
haematological malignancies or after HSCT. The mortality rate of P. jirovecii pneumonia …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia with infections a
leading cause of morbidity and mortality. Recently there has been a paradigm shift from the …

The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL)
has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a …

Pneumocystis jiroveci pneumonia (PCP) is frequently reported in lymphoma patients treated
with rituximab-contained regimens. There is a trend toward a difference in PCP risk between …

BACKGROUND: Significant improvement in overall survival observed in patients on clinical
trials and US Food and Drug Administration approval of two chimeric antigen receptor (CAR) …

This systematic review evaluates the current global impact of invasive infections caused by
Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World …

Abstract Purpose of Review Patients diagnosed with CLL have an increased susceptibility to
infections. Over the years, there has been a shift of the treatment arsenal to an increasing …

Early diagnosis and prompt initiation of effective therapy for infection help reduce morbidity
in ICHs. Advances in diagnostic assays using nonculture-based methods, such as nucleic …